AskBio Reports Interim Safety Data from Phase 1/2 LION-CS101 Trial of AB-1003 in Limb-Girdle Muscular Dystrophy 2I/R9 AskBio Inc. (AskBio), a gene therapy company wholly owned by Bayer AG and operated independently, today announced that it will present initial safety…
Satellos Bioscience Reports Promising Safety, Tolerability, and Functional Benefits of SAT-3247 in Adults with Duchenne Muscular Dystrophy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing transformative therapies for degenerative muscle diseases, has unveiled new…
Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG, has announced the publication of a pivotal manuscript in Science…
Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing Through ReproTracker® Collaboration Charles River Laboratories International, Inc. (NYSE: CRL) and Dutch biotechnology company Toxys have announced a strategic collaboration that aims to reshape the landscape of developmental and…
RIBOMIC’s Umedaptanib Pegol Achieves Strong Growth Outcomes in Children with Achondroplasia: Phase 2 Data Support Advancement to Late-Stage Clinical Development RIBOMIC, Inc. (TOKYO: 4591), a Japan-based clinical-stage biotechnology company focused on aptamer therapeutics, announced highly encouraging results from its Phase…
DemeRx Secures $1.7 Million NIH Grant to Advance First-in-Class Neuroplastogen DMX-1001 for Alcohol Use Disorder DemeRx, Inc., a clinical-stage biopharmaceutical company committed to transforming addiction therapeutics through innovative neuroscience, announced that it has been awarded a $1.7 million Small Business…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…
Merck Reports Clinical Positive Phase 3 HYPERION Trial Results for WINREVAIR™ (sotatercept-csrk) in Newly Diagnosed Pulmonary Arterial Hypertension Patients Merck known as MSD outside the United States and Canada, today announced encouraging findings from the Phase 3 HYPERION trial evaluating…
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative therapies for life-threatening diseases, has announced the publication of Phase…
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05 phase 3 clinical trial have reinforced the potential of ENHERTU®…
Savara Presents New Phase 3 IMPALA-2 Data on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025 Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies for rare respiratory diseases, announced the presentation of new analyses…
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering patient-specific therapies for rare diseases, has announced the publication of…